Chief Executive Officer — IntegerBio, Inc.

Atul Saran is currently the Chief Executive Officer of IntegerBio, Inc., a pioneering immunovirology biotech company. Previously, he was an executive officer at Emergent BioSolutions where he held several general management roles, including Chief Strategy and Development Officer with responsibility for all research and development from February 2022 through March 2023, as well as Executive Vice President, Corporate Development, General Counsel, and Corporate Secretary from May 2017 through February 2022. Before that he served as the Senior Vice President and General Counsel for MacroGenics, a clinical-stage oncology company from May 2013 through April 2017. Prior to that, he held various positions of increasing responsibility in the legal department at MedImmune/AstraZeneca from February 2003 through December 2009 culminating as Deputy General Counsel before assuming leadership for global biologics corporate development and venture investing activity for the AstraZeneca group from January 2010 through January 2014. Before taking an in-house role, Mr. Saran was a practicing attorney in the Hogan & Hartson Business & Finance Group from April 1999 through January 2003.

Mr. Saran holds an MBA from the MIT Sloan School of Management, a JD from the University of Illinois College of Law, a BS in Biological Sciences from Stanford University, and completed all coursework and Step 1 of the USMLE towards an MD from the University of Illinois. He has previously served as a director on several board of directors including Arriva, VentiRx, and Xencor.